TY - JOUR
T1 - Incidence and survival differences in esophageal cancer among ethnic groups in the United States
AU - Chen, Zheling
AU - Ren, Yinghong
AU - Du, Xianglin L.
AU - Yang, Jiao
AU - Shen, Yanwei
AU - Li, Shuting
AU - Wu, Yunying
AU - Lv, Meng
AU - Dong, Danfeng
AU - Li, Enxiao
AU - Li, Wei
AU - Liu, Peijun
AU - Yang, Jin
AU - Yi, Min
N1 - Publisher Copyright:
© Chen et al.
PY - 2017
Y1 - 2017
N2 - Objectives: This study was performed to identify the differences in incidence, clinicopathological features, and survival in esophageal cancer among ethnic groups in the United States and to determine the reasons for the differences. Result: A total of 49,766 patients were included. Black and Asian groups had a higher proportion of squamous cell carcinoma (ESCC) (85.5% and 75.4%, respectively) and mid-esophagus tumor (43.2% and 37.7% respectively) than the non-Hispanic white and Hispanic white groups. The incidences of ESCC in all ethnic groups declined since 1973, especially in black males. At the same time, incidences of esophageal adenocarcinoma (EAC) dramatically increased in white males since 1973. And incidences of ESCC and EAC were the lowest and stable in Asian female. Multivariable models showed that patients who were male, or black, or had larger tumors, or positive lymph nodes had an increased risk of death from esophageal cancer, while patients with ESCC or diagnosed after 2005 or treated with surgery had a lower likelihood of death. For ESCC, the black patients had the lowest DSS, while for EAC there were no significant differences in DSS among the ethnic/racial groups. Materials and Method: From the Surveillance, Epidemiology, and End Results Program database, patients diagnosed with esophageal cancer from 1998-2013 were identified. Differences in incidences, clinicopathological features, treatments, and disease-specific survival (DSS) in four broad racial/ethnic groups were compared. Conclusion: Histological type distribution between racial groups could be an important consideration in the incidence and the survival trend but other factors could also have an effect.
AB - Objectives: This study was performed to identify the differences in incidence, clinicopathological features, and survival in esophageal cancer among ethnic groups in the United States and to determine the reasons for the differences. Result: A total of 49,766 patients were included. Black and Asian groups had a higher proportion of squamous cell carcinoma (ESCC) (85.5% and 75.4%, respectively) and mid-esophagus tumor (43.2% and 37.7% respectively) than the non-Hispanic white and Hispanic white groups. The incidences of ESCC in all ethnic groups declined since 1973, especially in black males. At the same time, incidences of esophageal adenocarcinoma (EAC) dramatically increased in white males since 1973. And incidences of ESCC and EAC were the lowest and stable in Asian female. Multivariable models showed that patients who were male, or black, or had larger tumors, or positive lymph nodes had an increased risk of death from esophageal cancer, while patients with ESCC or diagnosed after 2005 or treated with surgery had a lower likelihood of death. For ESCC, the black patients had the lowest DSS, while for EAC there were no significant differences in DSS among the ethnic/racial groups. Materials and Method: From the Surveillance, Epidemiology, and End Results Program database, patients diagnosed with esophageal cancer from 1998-2013 were identified. Differences in incidences, clinicopathological features, treatments, and disease-specific survival (DSS) in four broad racial/ethnic groups were compared. Conclusion: Histological type distribution between racial groups could be an important consideration in the incidence and the survival trend but other factors could also have an effect.
KW - Esophageal cancer
KW - Ethnicity
KW - Incidence rate
KW - Survival
KW - The united states
UR - https://www.scopus.com/pages/publications/85024389270
U2 - 10.18632/oncotarget.16694
DO - 10.18632/oncotarget.16694
M3 - 文章
C2 - 28410201
AN - SCOPUS:85024389270
SN - 1949-2553
VL - 8
SP - 47037
EP - 47051
JO - Oncotarget
JF - Oncotarget
IS - 29
ER -